METiS TechBio (7666.HK) signed an exclusive global licensing agreement with US biotechnology firm Boulevard Bio, gaining rights to a trispecific T-cell engager targeting oncology indications.

METiS TechBio (7666.HK), a leading AI-driven drug delivery innovation company, today announced it has entered into an ...

In 2022, global production of construction materials accounted for more than 7% of total carbon emissions. But how many of ...

Across the country, hospitals and health systems are exploring innovative ways to improve quality of care and patient ...

Gensler's team tested a range of vendor-created generative AI tools, some of which are now integrated within an in-house ...

Arbor separates strategy from execution using isolated git worktrees, so engineering teams can finally trace which ...

It would be slightly ridiculous to reinvent your entire home every time a new interiors trend rolled around, but taking a closer look at what’s poised to define 2026 certainly has its merits. It can ...

Each year when MD+DI editors sit down to discuss Medtech Company of the Year prospects, the companies that rise to the top for us tend to be those that have had a transformational year either through ...

Modern seismic codes ensure life safety, but code-compliant buildings can still suffer significant economic losses from earthquake-induced damage, even during moderate events. Performance-Based ...

Search optimization now requires combining traditional SEO with AI-focused GEO and answer-driven AEO strategies AI search usage continues to grow, with 10% of US consumers currently using generative ...